Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

• DOI: 10.1200/jco.2007.14.8924
• Publication Date: 2008-07-15T01:09:36Z
• Authors: Chang-Qi Zhu; Gilda da Cunha Sa...; Keyue Ding; Akira Sakurada; Jean-Claude Cutz; Ni Liu; Tong Zhang; Paula Marrano; Marlo Whitehead; Jeremy A. Squire; Suzanne Kamel-Reid; Lesley Seymour; Frances A. Shepherd; Ming-Sound Tsao
• Keywords: Male; 0301 basic medicine; Canada; Lung Neoplasms; Genotype; Antineoplastic Agents; Genes, erbB-1; Middle Aged; Survival Analysis; 3. Good health; Proto-Oncogene Proteins p21(ras); Erlotinib Hydrochloride; 03 medical and health sciences; Predictive Value of Tests; Carcinoma, Non-Small-Cell Lung; Proto-Oncogene Proteins; Mutation; Quinazolines; ras Proteins; Humans; Female; In Situ Hybridization, Fluorescence

Purpose To evaluate the effect of KRAS and epidermal growth factor receptor (EGFR) genotype on the response to erlotinib treatment in the BR.21, placebo-controlled trial. Patients and Methods We analyzed 206 tumors for KRAS mutation, 204 tumors for EGFR mutation, and 159 tumors for EGFR gene copy by fluorescent in situ hybridization (FISH). We reanalyzed EGFR deletion/mutation using two highly sensitive techniques that detect abnormalities in samples with 5% to 10% tumor cellularity. KRAS mutation was analyzed by direct sequencing. Results Thirty patients (15%) had KRAS mutations, 34 (17%) had EGFR exon 19 deletion or exon 21 L858R mutations, and 61 (38%) had high EGFR gene copy (FISH positive). Response rates were 10% for wild-type and 5% for mutant KRAS (P = .69), 7% for wild-type and 27% for mutant EGFR (P = .03), and 5% for EGFR FISH-negative and 21% for FISH-positive patients (P = .02). Significant survival benefit from erlotinib therapy was observed for patients with wild-type KRAS (hazard ratio [HR] = 0.69, P = .03) and EGFR FISH positivity (HR = 0.43, P = .004) but not for patients with mutant KRAS (HR = 1.67, P = .31), wild-type EGFR (HR = 0.74, P = .09), mutant EGFR (HR = 0.55, P = .12), and EGFR FISH negativity (HR = 0.80, P = .35). In multivariate analysis, only EGFR FISH-positive status was prognostic for poorer survival (P = .025) and predictive of differential survival benefit from erlotinib (P = .005). Conclusion EGFR mutations and high copy number are predictive of response to erlotinib. EGFR FISH is the strongest prognostic marker and a significant predictive marker of differential survival benefit from erlotinib.